Navigation Links
Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference

What this robust clinical trial established was that nebulized formoterol fumarate, given at 20 mcg/2 mL twice daily, was well tolerated for maintenance treatment over the full 12 weeks of the trial. The side effect profile of Perforomist™ Inhalation Solution was similar to that of Foradil®, the active comparator, and the product was associated with fewer COPD exacerbations than placebo. Significantly, repeated testing for cardiac effects showed nothing to suggest a problem, a highly significant finding for the well-being of this group of patients.”

The research presented today was supported by a grant from Dey, L.P., which developed and will market Perforomist™ Inhalation Solution.

“DEY is the US leader in nebulized respiratory medication, and bringing the first nebulized formoterol fumarate to market is central to our overall strategy,” commented Mel Engle, President and CEO of DEY. “We are highly gratified by the positive safety and efficacy outcomes from the Phase III pivotal study, and thank Drs. Gross and Nelson for their careful oversight of the research and enthusiastic support of these important data. COPD patients and their families will be well served by this new treatment, which for the first time will allow twice-daily treatment with a proven LABA molecule via nebulization, a time-tested and reliable drug delivery option.”

About Perforomist™ (Formoterol Fumarate) Inhalation Solution
The clinical evaluations of Perforomist™ Inhalation Solution included two clinical trials involving a total of 1,045 patients. In the product’s pivotal Phase III trial, 351 patients participated in a 12-week, multi-center, safety and efficacy COPD study. In the study, 123 COPD patients were treated with Perforomist™ Inhalation Solution 20 mcg/2 mL twice daily, 114 COPD patients were treated with the active comparator (Foradil®), and 114 COPD patients were treated wi
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:10/30/2014)... 30, 2014  The number of retail health clinics ... growing steadily, thanks to drug store chains, according to ... the economic downturn, retail clinic growth had been at ... as the number of retail clinics reached nearly 1,600 ... Clinics Market Overview and 2014 Consumer Survey Results .  ...
(Date:10/30/2014)...  Nektar Therapeutics (Nasdaq: NKTR ) will ... September 30, 2014 on Thursday, November 6, 2014, after ... , president and chief executive officer, will host a ... p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... Webcast of the conference call can be accessed through ...
(Date:10/30/2014)... 2014 China Biologic Products, Inc. (NASDAQ: CBPO, ... plasma-based biopharmaceutical company in China , ... quarter 2014 financial results on Wednesday, November 5, 2014 ... management will hold a conference call at 7:30 a.m. ... 8:30 p.m., Beijing Time on November 6, 2014, to ...
Breaking Medicine Technology:Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2China Biologic to Report Third Quarter 2014 Financial Results 2
... 28 Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS ) ... (formerly SNS-595) at two major upcoming,oncology conferences., ... clinical trial of,voreloxin in platinum-resistant ovarian cancer patients ... Clinical Oncology (ASCO) Annual Meeting,being held May 30 ...
... for lupus on track for ... 2010 -,- ABthrax(TM) for inhalation anthrax on track to begin delivery fall 2008 -, ... ... GSK to advance darapladib to Phase 3 for atherosclerosis -, ROCKVILLE, Md., May 28 ...
Cached Medicine Technology:Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress 2Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress 3Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 2Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 3Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 4Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 5Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 6Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 7Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 8Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 9Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 10Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives 11
(Date:10/30/2014)... and her research group at the DFG Research Center ... the TU Dresden (CRTD) demonstrated for the first time ... cord in three dimensions from mouse embryonic stem cells. ... interneurons along the dorsal/ventral axis was observed., This study ... " Stem Cell Reports " on 30.10.2014 ., For ...
(Date:10/30/2014)... Florida (PRWEB) October 30, 2014 Timothy, ... visit to Pompano Beach firefighters, showing that you are ... , Timothy met firefighters Tracey and Carl at ... Galuppi’s Restaurant and the Pompano Beach Chamber of Commerce. ... the fire truck, letting Timothy wear his real fireman’s ...
(Date:10/30/2014)... Diego, Calif. (PRWEB) October 30, 2014 ... longer mutually exclusive concepts in the medical-grade skin ... on the development of uniquely potent topical dermatological ... Health System ( http://www.RefinitySkinScience.com ) with patented COSMEDERM®-7 ... available glycolic acid concentrations (50% and 70%) and ...
(Date:10/30/2014)... Paramount Rx, a full-service prescription benefits ... to help people save money through its innovative discount ... prescription drugs in the new health care system, the ... bridge the relationship between consumers, businesses and the pharmacy ... people face today with medical costs is the rising ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. 29, ... been identified that appear linked to autism spectrum disorders, ... are on their way to discovering up to 1,000 ... Autism spectrum disorders include a range of developmental disabilities ... An estimated one in 68 U.S. children has an ...
Breaking Medicine News(10 mins):Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3
... law firm files notice of claim against City of New York ... ... NY (Lexis Nexis) August 28, 2008 -- http://thesandersfirm.com/attorney.asp?attorneyid=14 [Marc ... Sanders, Sanders, Block, Woycik, Viener & Grossman, P.C. in Bronx, New ...
... Efforts to Create Sensible Fire Safety ... Legislation, ... voted to maintain California,s tough fire,standards by striking down proposed fire retardant ... sensible,legislation to address fire safety regulations in the state. The bill would,have ...
... gain access to innovative medical, education and news ... radio channel created for medical professionals by medical ... 157 announced today a new,strategic programming partnership with ... and largest, independent,association for physicians-in-training., Gary Epstein, ...
... American Society for Therapeutic Radiology and Oncology has selected ... honorary member. Dr. Evans will be recognized during the ... during ASTRO,s 50th Annual Meeting in Boston., Dr. Evans ... study of childhood cancer for decades. She was one ...
... cuts risk in half, study finds , , WEDNESDAY, Aug. 27 ... of preterm delivery, cut the rate of cerebral palsy in ... "If deemed to be at high or immediate risk of ... consider using magnesium sulfate to prevent their child from having ...
... treating ,wet, form of the eye disease , , WEDNESDAY, ... States and China have identified the first gene directly ... one of two forms of age-related macular degeneration that ... older Americans. , The discovery, based on work with ...
Cached Medicine News:Health News:New York-Based Sanders Law Firm Files Claim for Good Samaritan Beaten by New York City Police Officers 2Health News:California Senate Rejects Proposed Effort to Weaken Fire Safety Standards 2Health News:ReachMD, LLC Announces New Strategic Partnership With The American Medical Student Association 2Health News:ReachMD, LLC Announces New Strategic Partnership With The American Medical Student Association 3Health News:ASTRO selects pediatric oncologist as 2008 honorary member 2Health News:Magnesium Sulfate Reduces Threat of Cerebral Palsy 2Health News:Magnesium Sulfate Reduces Threat of Cerebral Palsy 3Health News:Gene Linked to 'Dry' Macular Degeneration 2Health News:Gene Linked to 'Dry' Macular Degeneration 3
... 45° Prism is designed ... and are recommended for ... BRVO etc.) and Rhegmatogenus ... be used for panretinal ...
The Chalam Mid Field lens can be used for air/gas exchange and has a bi-concave design to provide the widest field available in a direct image surgical lens. This lens was developed with K.V. Chalam,...
... patented ACS lenses offer the high resolution, ... the original clariVits. The simple two part ... its integrity during surgery. Simply autoclave, add ... then lock together for use. (ACS) AutoClave ...
... With somewhat higher magnification and ... is best suited for detailed ... The Central Retinal is ideal ... in membrane peeling in proliferative ...
Medicine Products: